Few developments reshaped interventional cardiology as significantly as the shift from bare-metal stents to drug-eluting stents. Understanding drug eluting stent vs bare metal stent differences is less about declaring one universally superior and more about recognizing what problem drug-eluting technology was designed to solve, and where bare-metal stents still have a role in contemporary practice.
What Is a Bare-Metal Stent?
A bare-metal stent (BMS) is a metal mesh scaffold, typically made of stainless steel or a cobalt-chromium alloy, that holds a coronary artery open after angioplasty without any drug coating. Bare-metal stents were the first stent technology widely adopted in interventional cardiology, representing a major advance over balloon angioplasty alone by providing mechanical scaffolding that reduced acute vessel recoil and abrupt closure. Their principal limitation, recognized as their use grew, was a comparatively higher rate of in-stent restenosis driven by intimal hyperplasia — the vessel's own healing response overshooting and renarrowing the treated segment.
What Does a Drug-Eluting Stent Add?
A drug-eluting stent (DES) uses the same basic metal scaffold concept but adds a coating that releases an antiproliferative drug — commonly sirolimus or related compounds — directly into the vessel wall over time, specifically targeting the smooth muscle cell proliferation responsible for restenosis. This localized drug delivery is designed to substantially reduce the incidence of in-stent restenosis compared with bare-metal stents, which is why DES became the dominant stent choice in most coronary interventions following its introduction and subsequent generations of refinement.
The Antiplatelet Therapy Trade-Off
Because a drug-eluting coating can slow the normal healing process of the vessel wall becoming fully covered by endothelial cells, DES implantation is generally associated with a longer recommended duration of dual antiplatelet therapy (DAPT) compared with bare-metal stents, to reduce the risk of stent thrombosis while endothelialization completes. Bare-metal stents typically endothelialize more quickly and have historically been associated with shorter recommended DAPT courses, which is one reason BMS were, for a period, still considered for patients with a higher bleeding risk or an anticipated need for surgery requiring interruption of antiplatelet therapy soon after stenting.
Why Bare-Metal Stents Are Less Commonly Used Today
As DES technology matured through successive generations — thinner struts, more biocompatible or biodegradable polymers, and refined drug-elution kinetics — much of the original concern about prolonged DAPT and delayed healing narrowed considerably, and many contemporary DAPT guidelines now recommend similar durations regardless of stent type in a broad range of patients. This convergence has made BMS a comparatively uncommon choice in current practice, though it remains available and may still be considered in select circumstances, such as specific bleeding-risk profiles, at the discretion of the treating cardiologist.
How the Decision Is Actually Made Today
Choosing between DES and BMS, in the rare cases where BMS is still considered, depends on individualized factors: bleeding risk, anticipated adherence to antiplatelet therapy, upcoming surgical plans, and vessel or lesion characteristics. A qualified physician weighs these considerations against current clinical guidelines, since neither stent type is universally preferable across all patients — the decision is a matter of matching device characteristics to individual clinical circumstances.
INVAMED's ATLAS DES Coronary Stent
INVAMED manufactures the ATLAS Drug Eluting Coronary Stent System, a cobalt-chromium platform designed to reduce restenosis in coronary artery disease. According to manufacturer-reported specifications, the stent features a sirolimus coating at 1 µg/mm² on a thin-strut, 60 µm cobalt-chromium L605 alloy platform, with a nominal pressure of 9–10 atm and a rated burst pressure of 14–16 atm. Details are available on the ATLAS Coronary Stent System product page. INVAMED also references a stainless steel coronary stent platform in its portfolio; availability and specific indications for either platform vary by country, so the Instructions for Use (IFU) should always be consulted. See the coronary artery disease device category for the full stent portfolio.
Is one stent type simply "better" than the other?
Neither stent type is universally superior; drug-eluting stents generally show lower restenosis rates in most patients, while bare-metal stents may still be considered in specific situations involving bleeding risk or anticipated interruption of antiplatelet therapy. The appropriate choice depends on individual clinical circumstances determined by the treating physician.
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.